Allergan Botox tweet breaches UK pharma's Code of Practice
The Prescription Medicines Code of Practice Authority (PMCPA) ruled Allergan breached the Code on several counts after an employee accidentally tweeted publicly about Botox.
Best known as a cosmetic anti-wrinkle treatment, Botox is also indicated for a number of prescription-only uses in the UK, including certain spasticity associated with stroke in adults.
The PMCPA therefore decided Allergan had in effect advertised a prescription only medicine to the general public, breaking one of the Code’s most important rules.
Issuing its ruling, the PMCPA said: “Pharmaceutical company employees needed to ensure that business relationships and personal relationships were kept very separate particularly when such business relationships were subject to the Code.
“In the Panel’s view, pharmaceutical company employees needed to be extremely cautious when using social media.”
Read more here...
See Full Case Report Attached